Brief: Kintara Therapeutics Announces Preliminary Topline Results From GBM Agile Study

TuHURA Biosciences

31/10/2023 12:02

Oct 31 (Reuters) - Kintara Therapeutics Inc  KTRA.O :
    * KINTARA THERAPEUTICS ANNOUNCES PRELIMINARY TOPLINE RESULTS
FROM
GBM AGILE STUDY
    * KINTARA THERAPEUTICS INC - VAL-083 DID NOT PERFORM BETTER
THAN
CURRENT STANDARDS OF CARE
    * KINTARA THERAPEUTICS INC - COMPANY SUSPENDING DEVELOPMENT
OF
VAL-083, SHIFTING FOCUS TO REM-001 PROGRAM AND OTHER STRATEGIC
OPPORTUNITIES
    * KINTARA THERAPEUTICS INC - EXPECTS TO ENROLL FIRST SUBJECT
IN A
15-PATIENT CMBC STUDY AROUND END OF CALENDAR YEAR 2023.
    * KINTARA THERAPEUTICS - WILL EVALUATE A WIDE RANGE OF
STRATEGIC
OPTIONS AIMED AT POTENTIALLY MAXIMIZING SHAREHOLDER VALUE.

Source text for Eikon:  ID:nPnb58wJLa 
Further company coverage:  KTRA.O